TCRCure Biopharma Ltd. aims to develop next generation cancer immunotherapies that control tumor progression, convert cancers to manageable chronic diseases, and eventually lead to a cure.
TCRCure Biopharm was established in 2016, with engineered immune cells as the ultimate target, focusing on the innovative R&D and commercializing of tumor immune cell therapy technology.Through rolling development of CAR-T, TCR-T, CAR-NK and TIL immune cell therapy products, we aim to reduce the mortality, and recurrence rate caused by tumors, and also improve the quality of life of our patients. During the past five years, more than a dozen product pipelines have entered clinical stage, providing treatment to more than 60 patients.
TCRCure Biopharm has an international research team led by members of the United States and the Chinese Academy of Sciences, with rich experience in the field of cell therapy. Scientific founders Professor Qijing Li and Pin Wang brought decades of immunology, cell and virus engineering knowledge to TCRCure. The first CAR-T IND application was filed in their hand and they had given the CAR-T treatment to over 100 patients. Professor Mark Davis, Chairman of the Scientific Committee, is the first scientist in the world to clone T cell receptor (TCR). Professor Xiaofan Wang, Scientific Consultant, is a foreign member of the Chinese Academy of Sciences, and has made key contributions in many tumor-related fields such as cell signal transduction, DNA damage and repair, and tumor microenvironment.
TCRCure Biopharm currently operates in Los Angeles, North Carolina, and Chongqing and Guangzhou. TCRCure has invested hundreds of millions of funds to build development and production base for gene and cell drugs in Nansha, Guangzhou and Los Angeles, the United States.
There are more than 150 employees working for TCRCure Biopharm globaly, of which more than 40% hold Masters and Ph.D Degrees. The management team comes from well-known international pharmacutical companies such as Johnson & Johnson, Novartis, Roche, etc., with rich industrial experience.
TCRCure Biopharm maintains a good cooperative relationship with many famous hospitals domestical and abroad. It has carried out clinical translational research and human clinical trials with top hospitals such as Sun Yat-sen Medical University Cancer Hospital, Xinqiao Hospital, West China Hospital, Beijing Tiantan Hospital and Fudan University Cancer Hospital.
TCRCure Biopharm has completed multiple rounds of financing, with a total financing amount of more than 600 millions. The shareholders come from well known international and Chinese pharmaceutical companies, and US and China medical VC. It is preparing for Cross Over fund raising and planning to go IPO in 2023